Macy, M. E., Naranjo, A., Zhang, F. F., Acord, M., Cash, T., DuBois, S. G., Foster, J. H., Knight, K. R., Hogarty, M. D., Mody, R., Morgenstern, D. A., Parisi, M. T., Pinto, N., Reynolds, C. P., Keyel, M. E., Shulkin, B. L., Ziegler, D. S., Bagatell, R., Park, J. R., Goldsmith, K. C. (2025). A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) report.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.10001